Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003313 · ClinicalTrials.gov registry record · Phase 3
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 243
- Enrollment target
NCT00003313 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 243 participants.
The verdict
NCT00003313, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 243 participants
- Enrollment target
Study Summary
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and radiation therapy.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- BIOLOGICAL filgrastim
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 1998-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003313
The ClinicalTrials.gov registry entry for NCT00003313 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00003313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003313 about?
NCT00003313 is a clinical study titled "Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer". RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III tri...
What is the current status of trial NCT00003313?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 243 participants. The study started on 1998-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00003313?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), filgrastim (BIOLOGICAL), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003313?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.